Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at Stifel Nicolaus

Stifel Nicolaus reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report issued on Tuesday, Benzinga reports. They currently have a $204.00 price target on the stock, up from their previous price target of $178.00.

KRYS has been the topic of a number of other reports. Guggenheim upped their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a buy rating in a report on Tuesday, February 27th. William Blair reaffirmed an outperform rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Finally, Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a buy rating in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech presently has an average rating of Buy and a consensus price target of $164.22.

Krystal Biotech Stock Up 0.2 %

Shares of KRYS stock opened at $170.09 on Tuesday. Krystal Biotech has a 12-month low of $82.09 and a 12-month high of $189.97. The firm has a market capitalization of $4.85 billion, a price-to-earnings ratio of 2,126.39 and a beta of 0.85. The firm has a fifty day moving average of $156.57 and a 200-day moving average of $129.21.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period last year, the firm earned ($1.25) earnings per share. Research analysts expect that Krystal Biotech will post 1.61 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 2,500 shares of Krystal Biotech stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total transaction of $325,000.00. Following the completion of the transaction, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,632,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 2,500 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the completion of the sale, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,632,280. The disclosure for this sale can be found here. Insiders have sold 40,587 shares of company stock worth $6,535,591 over the last quarter. Corporate insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its holdings in Krystal Biotech by 50.0% in the second quarter. PNC Financial Services Group Inc. now owns 372 shares of the company’s stock worth $44,000 after purchasing an additional 124 shares during the period. Osaic Holdings Inc. grew its holdings in Krystal Biotech by 193.3% in the second quarter. Osaic Holdings Inc. now owns 396 shares of the company’s stock worth $46,000 after purchasing an additional 261 shares during the period. West Tower Group LLC grew its holdings in Krystal Biotech by 413.1% in the fourth quarter. West Tower Group LLC now owns 431 shares of the company’s stock worth $53,000 after purchasing an additional 347 shares during the period. KBC Group NV acquired a new stake in Krystal Biotech in the fourth quarter worth $59,000. Finally, Lazard Asset Management LLC grew its holdings in Krystal Biotech by 52.4% in the second quarter. Lazard Asset Management LLC now owns 713 shares of the company’s stock worth $82,000 after purchasing an additional 245 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).